Thursday 15 April 2021: Navitas Life Sciences, a wholly owned subsidiary of TAKE Solutions and provider of Pharmacovigilance, Regulatory, and Clinical solutions and services today announced that it has been recognized as a ‘Major Contender’ in the Everest Group’s Pharmacovigilance and Complaint Management Operations – Services PEAK Matrix® Assessment 2021.
The PEAK Matrix® assessment provides the analysis and insights that enterprises need to make critical selection decisions about service providers, locations, and products and solutions. For this research report, Navitas Life Sciences is one of 22 global service providers to feature. The report provides a comprehensive picture of service focus, key solutions, domain investments, and case studies.
Having long been considered a cost-function, the report suggests that the Pharmacovigilance and Complaint Management market is finally getting long overdue attention from all industry sections, including Regulatory Agencies, Drug Safety Teams, and the media. Such attention stresses the need to effectively monitor both drugs and devices and prioritize patient safety. In response the industry is pursuing strategic technology investments and realigning its focus on value-add drug safety activities while outsourcing a number of PV services to third party providers. Such providers are helping organizations to address these challenges by providing well-established drug/device vigilance processes and services, offering staff augmentation capabilities with access to highly trained resources, and supporting regional QPPV activities.
Marty Boom, Global Head of Regulatory and Safety at Navitas Life Sciences said, “Navitas Life Sciences has been recognized for many years as a trendsetter in the PV space through our Consulting Team and our industry leading networks pvnet®, pvconnect®, pvtech®, and pvindia®. Over the last two years we have invested in becoming an all-round End-to-End PV Services provider. Being recognized by Everest as a major contender confirms that we are successfully progressing in our journey and that, by challenging the status quo based on our experience and knowledge of PV, we can offer a partnership model to our clients that benefit them hugely in terms of cost, quality, and compliance.”
Navitas has been at the forefront of new developments in Pharmacovigilance for more than 30 years. The Company’s Consulting Team has defined and implemented PV processes, governance practices and even organizations in more than 300 Life Sciences companies. Many of the top 100 biopharma companies are members of pvnet or pvconnect, our Safety Networks. They benefit from round-the-year insights on operational performance, compliance and the latest trends highlighted during our forums, and frequent interactions with our experts. This wealth of experience and PV knowledge combined with our Technology capabilities is utilized across all our PV services and solutions.
For further information, or to read the Everest Group’s Pharmacovigilance and Complaint Management Operations – Services PEAK Matrix® Assessment 2021 please visit: https://www2.everestgrp.com/reportaction/EGR-2021-54-R-4242/TOC
About Navitas Life Sciences
Navitas Life Sciences delivers platform-driven full-service Clinical, Regulatory, and Safety solutions and services. As the dedicated life sciences brand of TAKE Solutions, Navitas Life Sciences operates across North America, Europe, Asia Pacific, and Latin America. Navitas brings together the capabilities of a full-service CRO, a technology-led life sciences services provider, and expertise in analytics and data sciences to address critical challenges and drive outcomes for life sciences.
Navitas has over 30 years of rich experience across 550+ phase I-IV clinical trials, 1100 bioequivalence studies, 20+ therapeutic areas, and 40+ successful GCP/non-GCP audits. Our trial expertise is augmented by OneClinical, a platform that delivers trial oversight, analytics, and insights to drive successful study outcomes. With over 50 strategic regulatory consulting engagements, Navitas has delivered 170,000+ submissions to a range of regulatory authorities across the globe.
Backed by insights derived from our proprietary industry networks, and over 300 strategic safety consulting engagements, Navitas supports both in-trial and post-authorization pharmacovigilance to ensure better patient safety. Over the last 17 years, our 10 proprietary industry networks have provided a platform for industry peers to share with and learn from each other. With over 120 members, the ‘nets’ drive the development and adoption of industry best practices and innovations.
Navitas Life Sciences brings together the best minds in the industry to provide life sciences companies with an adaptive, innovative, and reliable partner who delivers better outcomes consistently, across the value chain.
To learn more, visit www.navitaslifesciences.com.
For media information, contact:
Rajeswari Pradeep Kumar,
+91 44 66110700,